focus -WSS

focus

author：comprehensive 2025-10-02 11:04:49 - browse：428

Hevolution's executive team includes, from left, Sophia Pathai, Haya Bint Khaled Bin Bandar Al Saud, Mehmood Khan, and Salman AlAsiry. Courtesy Hashem Al-Sh

The Hevolution Foundation, a Saudi investment firm focused on aging science, said Wednesday that it is launching an incubator that will bring together experts from the scientific community, pharma, and multiple biotech VCs.

The incubator, called the Breakthrough Innovation Alliance, will give up to $1 million apiece to 10 different research initiatives over the next three years, allowing scientists and entrepreneurs to run preclinical research to determine whether the ideas hold any promise. The projects will be evaluated by a committee made up of representatives from Hevolution, Novo Nordisk, 5AM Ventures, RA Capital, and drug company EvoTec. The best projects will become the basis of new startups, co-funded by Hevolution.

It’s all part of Hevolution’s plan to funnel up to $1 billion each year into academic research and biotech startups that are focused on aging-related diseases and and helping people live healthier lives longer, or what is sometimes referred to as “healthspan.” As part of that effort, the firm also announced at a conference in the Saudi capital of Riyadh this week that it will give around $80 million to a handful of research initiatives, including $21 million to establish a partnership with the Buck Institute for Research on Aging.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Stroke deaths set to near 10 million globally by 2050

hotspot

WSS

Why age limits for politicians are a terrible idea

A virus, fished out of a lake, may have saved a man’s life

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Covid vaccine financial winners and losers, from Pfizer to Novavax

Abortion pill case raises question: who can sue the FDA?

FDA rejects Alnylam's heart disease treatment over insufficient data

knowledge

focus

hotspot

Alkermes shareholders re

When women are denied an abortion, their children fare worse than peers

Apple is now the first public company to be valued at $3 trillion

The Readout: Lenmeldy, GLP

Medical records are filled with copy

There's no autism epidemic. It's an autism diagnosis epidemic

How to save PrEP access — and even expand it

Merck drug for rare lung condition set for approval in U.S.

Anesthesiologist group: stop taking Ozempic before surgery

Supreme Court mifepristone arguments center on docs' right to sue

knowledge

Senate panel eyes new effort on drug shortages

Readout LOUD podcast: mifepristone case, GLP

Decaf coffee targeted by food safety group under obscure FDA rule

AI can decode, harness the power of the humane immune system

Readout LOUD podcast: mifepristone case, GLP

FDA rejects Alnylam's heart disease treatment over insufficient data

hotspot

focus

Wikipedia

hotspot